benzalkonium
Benzalkonium chloride, also known as BZK, BKC, BAC, alkyldimethylbenzylammonium chloride and ADBAC, is a type of cationic surfactant. It is an organic salt called a quaternary ammonium compound. In 2011, a large clinical trial designed to evaluate the efficacy of hand sanitizers based on different active ingredients in preventing virus transmission amongst schoolchildren was re-designed to exclude sanitizers based on benzalkonium chloride due to safety concerns. Benzalkonium chloride has been in common use as a pharmaceutical preservative and antimicrobial since the 1940s. While early studies confirmed the corrosive and irritant properties of benzalkonium chloride, investigations into the adverse effects of, and disease states linked to, benzalkonium chloride have only surfaced during the past 30 years. Benzalkonium chloride is classed as a Category III antiseptic active ingredient by the United States Food and Drug Administration. Ingredients are categorised as Category III when "available data are insufficient to classify as safe and effective, and further testing is required”. Benzalkonium chloride is excluded from the current United States Food and Drug Administration review of the safety and effectiveness of consumer antiseptics and topical antimicrobial over-the-counter drug products, meaning it will remain a Category III ingredient. The mechanism of bactericidal/microbicidal action is thought to be due to disruption of intermolecular interactions. This can cause dissociation of cellular membrane lipid bilayers, which compromises cellular permeability controls and induces leakage of cellular contents. Other biomolecular complexes within the bacterial cell can also undergo dissociation. Enzymes, which finely control a wide range of respiratory and metabolic cellular activities, are particularly susceptible to deactivation. Critical intermolecular interactions and tertiary structures in such highly specific biochemical systems can be readily disrupted by cationic surfactants. Benzalkonium chloride is a human skin and severe eye irritant. It is a suspected respiratory toxicant, immunotoxicant, gastrointestinal toxicant and neurotoxicant. — NCATS
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Earliest trial started Sep 30, 2013 (NCT01951391)
Timeline
No events for the selected filters.
Indications
Approved for
Mechanism of action
- Unspecified targetSurfactant
surfactant
Chemistry & pharmacology
SMILES
CCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1- Mol. weight
- 318.57 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBenzalkonium chloride ↗
- NCATS7N6JUD5X6Y ↗
- ChEMBLCHEMBL1187417 ↗
Also known as
- benzalkonium
- benzalkonium
- benzalkonium
- benzalkonium
- benzalkonium
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03686904 | Phase 4 | Sep 30, 2018 | Georgetown University, Next Science |
| NCT03323528 | Phase 4 | Feb 1, 2017 | Medice Arzneimittel Pütter GmbH & Co KG, University of Munster |
| NCT02012348 | N/A | Dec 31, 2013 | Colgate Palmolive, University of California, San Diego |
| NCT01951391 | N/A | Sep 30, 2013 | University of California, San Diego |
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of California, San Diego | Academic/Hospital | 2 | 2 | 1 | 2013 |
| Colgate Palmolive | For profit | 1 | 0 | 1 | 2013 |
| Georgetown University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Medice Arzneimittel Pütter GmbH & Co KG | For profit | 1 | 1 | 1 | 2017 |
| Next Science | For profit | 1 | 0 | 1 | 2018 |
| University of Munster | Academic/Hospital | 1 | 0 | 1 | 2017 |